Selective Capital Allocation Post-Peak Investment

According to Silicon Valley Bank, venture investment in U.S. and European women's health companies dropped from $3.2 billion in 2024 to approximately $2 billion in 2025, a 38% decline. The sector's share of overall healthcare venture deals also fell from 7.4% to 5.7%. Biopharma investment plummeted from $1.3 billion to $610 million, a 53% drop, placing the greatest pressure on drug developers. As capital increasingly flows toward AI-driven drug discovery, investors are now demanding seed-stage companies to demonstrate clinical progress and early revenue comparable to past Series A levels. This trend leads to greater dilution and delayed development timelines for early-stage companies, while capital becomes increasingly polarized toward late-stage, validated assets.

Beovu Reveals Commercialization Risks

Astellas Pharma (TSE:4503)'s Beovu (fezolinetant) is a non-hormonal menopausal vasomotor symptom treatment that blocks neurokinin-3 receptors (NK3R), and was approved as a commercial product by the FDA on May 12, 2023. Its 2025 revenue reached approximately $300 million, and first-quarter 2026 revenue remained around $100 million, constrained by slow demand generation and insurance coverage barriers. On December 16, 2024, the FDA added a boxed warning for rare but severe liver injury risks, increasing the burden of pre- and on-treatment liver function tests. This case illustrates the difficulty of rapidly transforming the approximately $19 billion global vasomotor symptom treatment market in 2025 with clinical success alone.

Lynkuet Approval Intensifies Non-Hormonal Competition

Bayer (ETR:BAYN)'s Lynkuet (elinzanetant), a dual NK1R and NK3R blocker, was approved by the FDA on October 24, 2025, for moderate to severe menopausal vasomotor symptoms. With the introduction of this direct competitor to systemic hormone therapy and the non-hormonal prescription drug paroxetine, Beovu now faces greater pressure to differentiate in pricing, coverage, and safety. While no revenue figures for Lynkuet have yet been disclosed, the competitive landscape has already formed, with market expansion and share fragmentation occurring simultaneously. For R&D companies, demonstrating not only efficacy but also liver toxicity profiles, sleep improvement, and insurance accessibility will be essential to command investment premiums.

Shrinking Investment and Resilient Exit Market

M&A activity in women's health companies in 2025 totaled 18 deals, down from 21 in 2024, but new IPOs rose to 14, rebounding from zero in the previous year. Sun Pharmaceutical Industries (NSE:SUNPHARMA) finalized a definitive agreement on April 26, 2026, to acquire Organon (NYSE:OGN) for $14 per share in cash, valuing the company at $11.75 billion, with the transaction expected to close in early 2027, subject to regulatory and shareholder approvals. Unicorns such as Flo Health, Medly Health, and Maven Clinic are expanding their total addressable market (TAM) beyond reproductive health to include menopause, cardiovascular, obesity, and depression data. Large acquisitions and digital health IPOs continue to support exit pathways, but therapeutic startups face ongoing structural re-evaluation requiring both clinical data and commercialization capabilities.